The October document is a draft
The federal health department, HHS, published a draft on October 30, 2026 concerning semax, KPV, epitalon, TB-500, BPC-157, and MOTS-c.
Source: HHS policy notice
In these pages, HHS shortens the name Department of Health and Human Services. A draft is a proposal. Here, compounding means mixing or changing medicine to order. The draft addresses whether the department would act over certain compounding. It is not a drug approval decision. The practical question for a care discussion is which conditions apply to the actual preparation being proposed, rather than whether a headline sounds favorable.
Who and what the draft covers
For a prescription naming a patient, the draft describes when HHS plans to hold back action over compounding. That plan applies only to state-licensed pharmacies or doctors meeting the draft’s conditions.
Source: HHS draft peptide policy
Checked November 3, 2026, the draft covers one ingredient per preparation and sets limits on the ingredient’s exact form and how it is given. It excludes blends, which mix ingredients, and makers registered under section 503B of federal law; it gives no FDA drug approval.
Source: HHS draft peptide policy
A 503B outsourcing facility registers with FDA to prepare germ-free medicines, often in batches for hospitals and clinics, under rules checked November 3, 2026.
Source: FDA on compounding
Ask the prescriber to identify who would prepare the medicine and which part of the draft they are relying on. A reference to the policy alone leaves those questions open.
The official ingredient list is separate
As of November 3, 2026, all six remain off FDA’s official raw-ingredient list for compounding under section 503A, the pharmacy part of federal law. The draft’s conditional plan to hold off on action is separate from that list and does not add the six to it.
Source: HHS draft peptide policy
A bulk substance is the raw active ingredient used to make a preparation. The official ingredient list, the HHS draft, and FDA drug approval answer different questions. Keep their names separate when taking notes. If someone says FDA has given permission, ask which document they mean and what exact decision it records.
Taking back a request does not approve a medicine
FDA’s safety page, marked current through April 22, 2026, lists withdrawn requests to consider certain raw ingredients for compounding and still describes its safety concerns.
Source: FDA ingredient review
Individual ingredients have no withdrawal dates shown on that page. Taking back a request grants no drug approval or compounding permission; the separate October 30, 2026 HHS draft describes when the department plans to hold off on action under its conditions.
Source: FDA ingredient review
Someone nominates an ingredient by asking FDA to consider it for the list. Withdrawal means the requester took it back. Avoid turning the page’s update date into a date for each individual entry.
Committee advice has its own place
In its October 30, 2026 publication, HHS reports that FDA’s Pharmacy Compounding Advisory Committee supported listing six of the seven peptides it considered in July 2026.
Source: HHS draft peptide policy
FDA’s meeting page still lacks minutes or a transcript, as checked November 3, 2026; the HHS account supplies an official report of the vote.
Source: HHS draft peptide policy
As of November 3, 2026, the committee’s advice does not itself change the official list or approve a drug.
Source: FDA ingredient rules
Bring the proposal back to your own care question. Ask the professional to identify the substance, the form, the source, the reason for considering it, and the evidence limits. Those details are more useful in a visit than a broad claim that the rules have changed.